Definium Therapeutics Financials
This page shows Definium Therapeutics (DFTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Definium Therapeutics passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Definium Therapeutics generates $0.72 in operating cash flow (-$131.6M OCF vs -$183.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Definium Therapeutics earns $-30.3 in operating income for every $1 of interest expense (-$166.3M vs $5.5M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Definium Therapeutics reported -$183.8M in net income in fiscal year 2025. This represents a decrease of 69.1% from the prior year.
Definium Therapeutics earned $-2.06 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 33.8% from the prior year.
Cash & Balance Sheet
Definium Therapeutics held $257.8M in cash against $40.6M in long-term debt as of fiscal year 2025.
Definium Therapeutics had 99M shares outstanding in fiscal year 2025. This represents an increase of 31.5% from the prior year.
Margins & Returns
Definium Therapeutics's ROE was -55.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 10.3 percentage points from the prior year.
Capital Allocation
Definium Therapeutics invested $117.7M in research and development in fiscal year 2025. This represents an increase of 80.2% from the prior year.
DFTX Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $31.0M+3.9% | $29.8M+27.6% | $23.4M | N/A | $17.2M+17.4% | $14.6M+25.1% | $11.7M |
| SG&A Expenses | N/A | $14.7M+32.4% | $11.1M+26.0% | $8.8M | N/A | $7.6M-22.5% | $9.8M-6.5% | $10.5M |
| Operating Income | N/A | -$45.7M-11.7% | -$40.9M-27.2% | -$32.2M | N/A | -$24.8M-1.4% | -$24.5M-10.2% | -$22.2M |
| Interest Expense | N/A | $1.3M-45.5% | $2.3M+288.4% | $602K | N/A | $727K+56.0% | $466K+7.4% | $434K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$67.3M-57.4% | -$42.7M-83.1% | -$23.3M | N/A | -$13.7M-133.8% | -$5.9M+89.2% | -$54.4M |
| EPS (Diluted) | N/A | $-0.78-56.0% | $-0.50-42.9% | $-0.35 | N/A | $-0.27-3.8% | $-0.26+77.2% | $-1.14 |
DFTX Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $440.1M+85.8% | $236.9M-10.6% | $265.1M-3.7% | $275.3M-8.9% | $302.2M-5.5% | $319.8M+19.3% | $268.1M-2.7% | $275.5M |
| Current Assets | $419.3M+94.3% | $215.8M+14.1% | $189.1M-14.7% | $221.7M-21.3% | $281.6M-5.9% | $299.4M+20.9% | $247.7M-3.0% | $255.5M |
| Cash & Equivalents | $257.8M+1191.8% | $20.0M-40.2% | $33.4M-59.7% | $82.9M-69.7% | $273.7M-7.3% | $295.3M+21.5% | $243.1M-3.6% | $252.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $19.9M0.0% | $19.9M0.0% | $19.9M0.0% | $19.9M0.0% | $19.9M0.0% | $19.9M0.0% | $19.9M0.0% | $19.9M |
| Total Liabilities | $107.8M+1.4% | $106.3M+33.4% | $79.7M+51.7% | $52.5M-13.5% | $60.7M+5.4% | $57.6M-12.9% | $66.1M-16.8% | $79.5M |
| Current Liabilities | $66.7M+2.0% | $65.4M+72.3% | $38.0M+24.5% | $30.5M-21.5% | $38.8M+16.8% | $33.3M-20.5% | $41.8M-35.9% | $65.3M |
| Long-Term Debt | $40.6M+0.5% | $40.4M-2.0% | $41.2M+86.9% | $22.0M+0.8% | $21.9M-10.1% | $24.3M+0.2% | $24.3M+70.9% | $14.2M |
| Total Equity | $332.3M+154.5% | $130.6M-29.6% | $185.4M-16.8% | $222.8M-7.7% | $241.4M-7.9% | $262.2M+29.8% | $202.0M+3.1% | $196.1M |
| Retained Earnings | -$582.7M-9.5% | -$532.2M-14.5% | -$465.0M-10.1% | -$422.2M-5.9% | -$398.9M-9.5% | -$364.1M-3.9% | -$350.5M-1.7% | -$344.6M |
DFTX Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$43.0M-45.3% | -$29.6M+0.1% | -$29.6M-0.6% | -$29.4M-16.0% | -$25.4M-47.5% | -$17.2M+14.0% | -$20.0M-20.4% | -$16.6M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $35.0M+127.1% | $15.4M+139.0% | -$39.5M+75.7% | -$162.5M | $0 | $0 | $0 | $0 |
| Financing Cash Flow | $245.9M+32726.2% | $749K-96.2% | $19.6M+1861.1% | $1.0M-73.7% | $3.8M-94.5% | $69.4M+542.9% | $10.8M-93.6% | $169.2M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
DFTX Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -51.5%-28.4pp | -23.1%-12.6pp | -10.5% | N/A | -5.2%-2.3pp | -2.9%+24.9pp | -27.8% |
| Return on Assets | N/A | -28.4%-12.3pp | -16.1%-7.6pp | -8.5% | N/A | -4.3%-2.1pp | -2.2%+17.6pp | -19.7% |
| Current Ratio | 6.29+3.0 | 3.30-1.7 | 4.98-2.3 | 7.27+0.0 | 7.25-1.8 | 9.00+3.1 | 5.92+2.0 | 3.91 |
| Debt-to-Equity | 0.12-0.2 | 0.31+0.1 | 0.22+0.1 | 0.100.0 | 0.090.0 | 0.09-0.0 | 0.12+0.0 | 0.07 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Frequently Asked Questions
Is Definium Therapeutics profitable?
No, Definium Therapeutics (DFTX) reported a net income of -$183.8M in fiscal year 2025.
What is Definium Therapeutics's earnings per share (EPS)?
Definium Therapeutics (DFTX) reported diluted earnings per share of $-2.06 for fiscal year 2025. This represents a -33.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
How much debt does Definium Therapeutics have?
As of fiscal year 2025, Definium Therapeutics (DFTX) had $257.8M in cash and equivalents against $40.6M in long-term debt.
What is Definium Therapeutics's return on equity (ROE)?
Definium Therapeutics (DFTX) has a return on equity of -55.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Definium Therapeutics's operating cash flow?
Definium Therapeutics (DFTX) generated -$131.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Definium Therapeutics's total assets?
Definium Therapeutics (DFTX) had $440.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Definium Therapeutics spend on research and development?
Definium Therapeutics (DFTX) invested $117.7M in research and development during fiscal year 2025.
How many shares does Definium Therapeutics have outstanding?
Definium Therapeutics (DFTX) had 99M shares outstanding as of fiscal year 2025.
What is Definium Therapeutics's current ratio?
Definium Therapeutics (DFTX) had a current ratio of 6.29 as of fiscal year 2025, which is generally considered healthy.
What is Definium Therapeutics's debt-to-equity ratio?
Definium Therapeutics (DFTX) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Definium Therapeutics's return on assets (ROA)?
Definium Therapeutics (DFTX) had a return on assets of -41.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Definium Therapeutics's cash runway?
Based on fiscal year 2025 data, Definium Therapeutics (DFTX) had $257.8M in cash against an annual operating cash burn of $131.6M. This gives an estimated cash runway of approximately 24 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Definium Therapeutics's Piotroski F-Score?
Definium Therapeutics (DFTX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Definium Therapeutics's earnings high quality?
Definium Therapeutics (DFTX) has an earnings quality ratio of 0.72x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Definium Therapeutics cover its interest payments?
Definium Therapeutics (DFTX) has an interest coverage ratio of -30.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.